Cite
HARVARD Citation
Özdemir, Ö. et al. (2022). The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anti-cancer drugs. 33 (7), pp. 663-670. [Online].